Prof Andrew Scott
Honorary Professorial Fellow
Department of Medicine
935 Scholarly works
2 Projects
HIGHLIGHTS
2026
Journal article
Assessment of Lean body mass using whole-body low-dose Ct from Pet/Ct to identify cancer Cachexia
DOI: 10.1186/s40644-026-01047-32026
Journal article
84 Phase 3 Study to Assess the Safety and Efficacy of 177Lu-girentuximab in Advanced, Relapsed or Recurrent ccRCC (LUTEON; NCT07197580)
DOI: 10.1093/oncolo/oyag312.0852026
Journal article
Monitoring glioblastoma dynamics during chemoradiation on the 1.5 T magnetic resonance imaging-linear accelerator
DOI: 10.1016/j.ctro.2026.1012002026
Journal article
A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma
DOI: 10.1158/1078-0432.CCR-25-36082026
Journal article
Clonal Hematopoiesis after177 Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
DOI: 10.1158/1078-0432.CCR-25-40012026
Research grants (ARC, NHMRC, MRFF)
Characterising the Plasma Proteome of Polymyalgia Rheumatica
2025
Research grants (ARC, NHMRC, MRFF)
Application of Molecular Imaging Biomarkers in Large Vessel Vasculitis and Polymyalgia Rheumatica
RECENT SCHOLARLY WORKS
2026
Journal article
SUBDUE-3: SUB-urothelial DUrvalumab-89zirconium injEction; a phase 0 biodistribution study protocol
DOI: 10.1111/bju.701532026
Journal article
iPREDICT: Phase II study of CD8 PET in patients with immunoresponsive solid tumors—Imaging characteristics and correlation with RECIST response.
DOI: 10.1200/jco.2026.44.16_suppl.30692026
Journal article
Cancer workforce—a global crisis: a Lancet Oncology Commission
DOI: 10.1016/S1470-2045(26)00065-32026
Journal article
Phase 3 study to assess the safety and efficacy of 177 Lu-girentuximab in advanced, relapsed, or recurrent ccRCC (LUTEON).
DOI: 10.1200/jco.2026.44.16_suppl.tps46312026
Journal article
Usefulness of CAIX-targeted PET in restaging clear cell renal cell carcinoma: detection of thyroid metastasis with [89Zr]Zr-girentuximab
DOI: 10.1016/j.eanmi.2026.100266